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Abstract
Background To investigate the long-term neurodevelopmental
outcome in children after hemolytic uremic syndrome (HUS)
and to compare outcome dependent on central nervous system
(CNS) involvement during HUS.
Methods A single-center retrospective cohort of 47 children
was examined at a median age of 10.6 (range 6–16.9) years
and a median follow-up of 7.8 (range 0.4–15.3) years after
having had HUS. Intellectual performance was assessed with
the German version of the Wechsler Intelligence Scale 4th
version and neuromotor performance with the Zurich
Neuromotor Assessment (ZNA). The occurrence of neurolog-
ical symptoms during the acute phase of HUS was evaluated
retrospectively.
Results Mean IQ of the whole study population fell within the
normal range (median full scale IQ 104, range 54–127).
Neuromotor performance was significantly poorer in the do-
mains “adaptive fine,” “gross motor,” “static balance” (all
p<0.05) and “associated movements” (p<0.001); only the
“pure motor” domain was within the normal reference range.
Neurological findings occurred in 16/47 patients (34 %) dur-
ing acute HUS. Neurodevelopmental outcome was not signif-
icantly different between children with or without CNS
involvement.
Conclusions Our follow-up of children after HUS showed a
favorable cognitive outcome. However, neuromotor outcome
was impaired in all study participants. Neurological impair-
ment during acute HUS was not predictive of outcome.
Keywords Intellectual . Motor . Neurocognitive outcome .
Central nervous system involvement . Hemolytic uremic
syndrome
Introduction
Hemolytic uremic syndrome (HUS) is a multi-organ and life-
threatening disease characterized by hemolytic anemia,
thrombocytopenia and acute renal injury. HUS is also one of
the most frequent causes of acute renal failure in childhood [1]
and may result in long-term renal and extrarenal sequelae
[2–5].
About 90 % of HUS cases in childhood are infection-
induced, i.e. they are typical HUS forms, mainly mediated
by infections caused by Shiga toxin-producing bacteria, usu-
ally enterohemorrhagic Escherichia coli (STEC-HUS) but in
some regions Shigella dysenteriae type 1. In addition, infec-
tions with Streptococcus pneumoniae (P-HUS) and other bac-
terial and viral agents can trigger HUS [6, 7]. Only 5–10 % of
cases are defined as atypical HUS (aHUS) based on various
hereditary and/or acquired disorders of the alternative com-
plement pathway regulation [6–8]. Renal replacement therapy
at disease onset is required in up to 65 % of STEC-HUS
patients [9], 84 % of those with P-HUS [10] and 59 % of
aHUS patients [5].
Extrarenal manifestations are frequent in all HUS forms,
including STEC-HUS [11, 12], P-HUS [13, 14] and aHUS [5,
15], and may affect the central nervous system (CNS), gastro-
intestinal tract, heart, eyes, lungs, parotid glands and skin.
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CNS involvement represents a major complication that is
associated with increased mortality [2, 11] and risk for neuro-
logical sequelae [16].
Studies reporting on neurodevelopmental outcome in chil-
dren after HUS are scarce, and the results suggest a normal
neurocognitive outcome [17–19]. However, a trend towards
impaired full-scale and verbal comprehension IQ in these
children has also been described [17]. Data on neuromotor
outcome are limited to information on impaired fine motor
skills in children with a history of HUS and severe CNS
involvement [18].
In the study reported here, we focused on the long-term
intellectual and neuromotor performance in a single-center
cohort of children after HUS, including typical and atypical
HUS forms. The hypothesis was that all children with HUS
may have a higher risk for adverse neurodevelopmental out-
come. Furthermore, the study was performed to determine the
influence of CNS involvement during acute HUS disease on
the long-term neurodevelopmental outcome.
Methods
Patients
The study cohort consisted of 47 children (22 males, 25
females; median age 10.6 years, age range 6–16.9 years) with
a history of both typical infection-induced HUS and atypical
HUS. The neurodevelopmental testing was part of a compre-
hensive single-center study on long-term renal outcome, psy-
chological adjustment and quality of life in HUS patients. The
study was approved by the Cantonal Ethics Committee Zurich
and registered at ClinicalTrials.gov (NCT 01666548). Written
informed consent was obtained by the parents and by the
adolescents themselves if they were ≥15 years. Inclusion
criteria for neurocognitive and neuromotor assessment were:
(1) previous diagnosis of HUS and (2) age between 6 years
and 16 years 11 months during the study period between
February 2012 and February 2013.
HUSwas defined as non-immunological hemolytic anemia
(hemoglobin<100 g/l), thrombocytopenia (thrombocytes
<150.000/μl) and features of acute renal injury (plasma creat-
inine elevation above the age-related norm range; proteinuria,
hematuria or renal ultrasound abnormalities). Two of the
enrolled patients—one with STEC-HUS requiring dialysis
and one with recurrent aHUS due to complement factor H
mutation—did not meet the criteria for thrombocytopenia.
The diagnosis of HUS in all patients was confirmed by pedi-
atric nephrologists. Based on the different approaches used in
published studies to classify HUS [20–22] we categorized the
disease as (1) typical, infection-induced HUS, including
STEC-HUS and P-HUS, and (2) aHUS based on currently
proposed HUS nomenclature [21].
The age criterion of 6–16 years was used to study long-
term neurocognitive outcome using one intellectual test,
namely, the German version of the Wechsler Intelligence
Scale 4th version [23].
Participants were recruited from a sample of 129 pa-
tients treated for HUS at the Pediatric Nephrology Unit of
Zurich University Children’s Hospital between April 1995
and February 2013. Seven patients died during an acute
episode of HUS, five patients were lost to follow-up and
42 patients did not fulfil the age criterion (26 were aged
<6 years and 16 were aged≥17 years). Thus, 75 patients
were eligible for the study. Twenty-six parents or children
refused to participate; two additional patients were ex-
cluded due to a pre-existing neurodevelopmental impair-
ment resulting from trisomy 21 in one and an unclassified
syndrome in another. The final study cohort included 47
(63 %) of the children originally eligible for entry.
Demographic and clinical characteristics did not differ
significantly between enrolled patients and those not en-
rolled in terms of sex, HUS form, socioeconomic status,
age at diagnosis of HUS, frequency of neurological com-
plications during the acute phase of HUS, occurrence of
anuria, need for dialysis during the acute phase of HUS,
length of hospital stay, estimated glomerular filtration rate
(eGFR) at time of discharge, need of dialysis at time of
discharge and development of end-stage renal disease
(ESRD).
The clinical and demographic data needed to evaluate
potential risk factors were extracted from patients’ records
and analyzed retrospectively. Values for the following
parameters were obtained from the medical records: sex,
age at disease onset, renal function, anuria defined as
urine output<0.2 ml/kg per hour, requirement of dialysis
and CNS involvement during the acute episode of HUS.
CNS involvement was defined as presence of neurological
findings including seizures, altered consciousness, ataxia,
muscle tone abnormalities, hemiplegic symptoms, dysar-
thria, visual disorders, movement disorders and vestibular
symptoms. Since conditions such as anemia or dehydra-
tion may affect mental status, CNS involvement was only
considered if the clinical symptoms were severe and not
attributable to an underlying non-cerebral medical condi-
tion. None of the studied children had a neurological
disease prior to HUS.
Other comorbidities and ESRD with renal replacement
therapy at follow-up were also recorded. Renal function was
evaluated by eGFR, expressed in millimeters per minute per
1.73 m2, according to the Schwartz formula using the local
factor k of 40 for all children and by the plasma creatinine
concentration (in μmol/l) [24]. Information on additional po-
tential neurological risk factors and interventions performed
since HUS was retrieved from parental interviews at the time
of neurodevelopmental assessment.
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Neurodevelopmental outcome assessment
The neurodevelopmental outcome assessment included as
assessment of intellectual and neuromotor performance and
a standardized neurological examination [25]; both were per-
formed at the Child Development Center of Zurich University
Children’s Hospital by one experienced developmental pedi-
atrician. Socioeconomic status was estimated based on mater-
nal education level and paternal occupation using an educa-
tion scale ranging from 2 to 12, with 2 being the lowest and 12
the highest education score [26].
Intellectual performance
Of the 47 participants, 46 were assessed using with the
German version of theWechsler Intelligence Scale 4th version
[23]. This test provides IQ subscales for verbal comprehen-
sion, perceptual reasoning, working memory and processing
speed, which together form the full-scale IQ. One 9-year-old
patient with P-HUS associated with meningitis and serious
neurological complications was not able to perform the
Wechsler Intelligence Scale 4th version and was examined
using the German version of the Wechsler Preschool and
Primary Scale of Intelligence 3rd version [27].
Neuromotor performance
Neuromotor performance was examined with the Zurich
Neuromotor Assessment (ZNA), a standardized, videotaped
test for children aged 5 to 18 years which is used to investigate
specific motor skills based on timed performances and move-
ment quality [28, 29]. The ZNA contains five block compo-
nents including: (1) pure motor domain, (2) adaptive fine
motor domain, (3) adaptive gross motor domain, (4) static
balance and (5) associated movements. The results are
expressed as z-scores, i.e. the standard score of the reference
population based on age and sex.
Statistical analysis
Statistical analysis was performed with SPSS for Windows
version 20.0 and 22.0 (IBM Corp,, New York, NY).
Differences between participants’ data and normative data
were calculated using the univariate t test, and differences
between subgroups were assessed using the Mann–Whitney
U test for continuous variables and Fisher’s exact test for
categorical variables. Multivariate linear regression was con-
ducted to evaluate the association between risk factors and
full-scale IQ scores. Variables included in the regression mod-
el were socioeconomic status, duration of hospital stay, CNS
involvement and eGFR at time of discharge. Two children
with very low full-scale IQ scores (54 and 62) were excluded
for the multiple regression analysis in order to complywith the
requirements of a normal distribution in the study sample. A p
value of<0.05 was considered to be statistically significant.
Results
Sample description
Forty-seven patients (22 boys and 25 girls; median age
10.6 years, range 6–16.9 years) with a history of STEC–HUS
(n=38), P-HUS (n=6) and aHUS (n=3) and a median follow-
up after HUS of 7.8 (range 0.4–15.3) years participated in this
study (for detailed information on each participant, see Table 1).
Of the 38 STEC-HUS patients, 24 tested positive for Shiga
toxin. Genetic analysis of the three aHUS patients revealed one
or more mutations of complement-related factors. The median
age at onset of HUS was 1.8 (range 0.3–14.4) years. Thirty-
three children (70 %) required acute renal replacement therapy
combined with either peritoneal dialysis (n = 24 patients),
hemofiltration or hemodialysis (n = 6) or a combination of both
treatment modalities (n = 3). At time of discharge the median
eGFR was 54 (range 13–178) ml/min per 1.73 m2. Forty-one
(87 %) patients had an impaired eGFR defined as<90 ml/min
per 1.73 m2. One patient was on dialysis when discharged and
remained on dialysis for 127 days, subsequently progressing to
ESRD. Five patients developed ESRD, of whom four
underwent renal transplantation (RTPL) (Table 1).
The median eGFR at neurodevelopmental testing—exclud-
ing the four children who underwent RTPL—was 113 (range
12–178) ml/min per 1.73m2; ten of these children had impaired
renal function with an eGFR of<90 (range 12–88) ml/min per
1.73 m2. Two of the four patients undergoing RTPL had good
renal graft function defined as an eGFR of>60 (respectively 92
and 163) ml/min per 1.73 m2, while the remaining two children
showed impaired graft function (47 and 54ml/min per 1.73 m2,
respectively). The children with CNS involvement has a sig-
nificantly lower median eGFR at both discharge and follow-up
(46 and 89ml/min per 1.73m2, respectively; p=0.014) than the
children without CNS involvement (83 and 126 ml/min per
1.73 m2, respectively; p=0.004) (Table 2).
CNS involvement during acute episode of HUS
Sixteen children (34 %) presented with CNS involvement
during the acute episode of HUS with a broad spectrum of
neurological symptoms, consisting predominantly of seizures
(12/16) or altered consciousness (7/16) (Table 3).
In the STEC-HUS group neurological symptoms were
observed in 12 of 38 patients. Two children received treatment
with plasmapheresis due to severe neurological complications
(Table 1). Four of the six P-HUS patients presented with
neurological symptoms, including two with pneumococcal
meningitis. None of the patients with aHUS manifested CNS
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involvement, but one was resuscitated due to respiratory fail-
ure following RTPL.
Neuroimaging studies were performed in 12 of 16 patients
with CNS involvement (cerebral computed tomography in 7,
cerebral magnetic resonance imaging in 5 and both investiga-
tions in 5 children), revealing cerebral abnormalities in five
patients: two with cerebral infarctions (both STEC-HUS), two
with meningitis-associated complications and one child with
leukoencephalopathy (P-HUS) (Table 1).
Comparison of clinical and demographic characteristics
between participants without and with CNS involvement dur-
ing the acute episode of HUS showed that anuria (p=0.006),
longer duration of hospital stay (p=0.03) and impaired eGFR,
both at discharge (p=0.01) and at time of neurodevelopmental
testing (p=0.004), were significantly more common in pa-
tients with CNS impairment (Table 2).
Additional comorbidities, not HUS related and potentially
leading to neurodevelopmental impairment, were present in
four children, with one child each having status after viral
meningitis and resuscitation for pulmonary edema after
RTPL, resuscitation associated with an anesthetic accident,
prematurity and attention deficit hyperactivity disorder treated
with methylphenidate, respectively. Two additional children
with P-HUS developed severe cerebral complications
(Table 1): subdural empyema and hydrocephalus, respectively.
Intellectual performance
The median full-scale IQ of the study cohort was normal with
a value of 104 {54–127 points; comparison to norm of 100
[±15=1 standard deviation (SD)]: p=0.39}. All subscales
were in the normal range: verbal comprehension [102 (range
Table 2 Demographic and clinical characteristics of the 47 hemolytic uremic syndrome (HUS) patients enrolled in the study
Demographic and clinical characteristics CNS involvement during acute episode
of HUS (n=16)
No CNS involvement during acute
episode of HUS (n=31)
p value
General data





Socioeconomic status score 8 (7–12) 8 (2–12) 0.38
Acute episode of HUS
Age (years) 1.3 (0.3–14.4) 2.2 (0.4–13.3) 0.24
Anuria (n) 14 14 0.006*
Duration of anuria (days) 8 (1–46) 9 (2–20) 0.58
Dialysis (n) 14 19 0.09
Duration of dialysis (days) 13 (5–79) 11 (3–23) 0.18
Mode of dialysis
Peritoneal dialysis (n) 9 14
Hemofiltration/hemodialysis (n) 4 2
Combination of peritoneal dialysis and
hemofiltration/hemodialysis (n)
1 3
Duration of hospital stay (days) 26 (10–97) 16 (5–54) 0.030*
eGFR at discharge (ml/min per 1.73 m2) 46 (13–125) 83 (14–178) 0.014*
Dialysis at discharge (n) 1 0 0.34
Follow–up
Age (years) 11.1 (6.3–16.3) 10.4 (6.0–16.9) 0.50
Time interval HUS to follow-up (years) 9.1 (0.6–15.3) 7.2 (0.4–15.1) 0.27
Development of ESRD (n) 2 3 1.00
Duration of dialysis in total (acute and chronic) (days) 13 (5–218) 12 (3–1560) 0.65
Status after RTPL (n) n 1 3 1.00
eGFR at neurodevelopmental examination (ml/min per 1.73 m2) 89 (12–141) 126 (47–178) 0.004*
*Significant difference at p< 0.05
Results are presented as the median with the range in parenthesis
CNS, Central nervous system; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; RTPL, renal transplant; STEC-HUS,
Escherichia coli hemolytic uremic syndrome; P-HUS, Streptococcus pneumoniae hemolytic uremic syndrome; aHUS, atypical hemolytic uremic
syndrome
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69–130); p–0.57], working memory [102 (54–144); p=0.52],
processing speed [100 (65–129); p=0.69] and perceptual rea-
soning [108 (61–129); p–0.03].
Six children (13 %) showed a full-scale IQ of<85 (−1 SD).
Two of these two patients had a full-scale IQ of<70 (−2 SD)—
one with P-HUS and pneumococcal meningitis and multiple
complications requiring ventriculoperitoneal shunt and co-
chlear implant and the second with a past history of resusci-
tation episode, aHUS and ESRD in infancy (Table 1).
Children with a history of ESRD showed a poorer
neurocognitive outcome than children without ESRD in terms
of verbal comprehension [88 (range 69–95) vs. 105 (79–130);
p=0.004], working memory [87 (54–102) vs. 102 (74–144);
p=0.008] and full-scale IQ [84 (54–103) vs. 105 (62–127);
p=0.010].
There were no significant differences between the 16 indi-
viduals with and the 31 individuals without CNS involvement
during the acute phase of HUS (Table 4). Socioeconomic status
did not differ between these two groups (Table 2). Furthermore,
the exclusion of patients with neurodevelopmental comorbidi-
ties (n=6) and those with development of ESRD (n=5) did not
significantly alter the results of the intellectual outcome.
Neuromotor performance
Forty-seven children (22 boys, 25 girls) performed the ZNA.
Except for the pure motor domain, all other domains of the
neuromotor performance were significantly impaired com-
pared to the normal controls (Table 5). Between 15 and
38% of the children performed poorer than the 10th percentile
within the five ZNA domains (Table 5).
Table 3 Neurological symptoms of the 16 patients enrolled in the study





Isolated altered consciousness 2/16
Ataxia 4/16






>1 neurological symptoms 8/16






Results are presented as the number of patients
CNS, Central nervous system; HUS, hemolytic uremic syndrome
Table 4 Intellectual performancea of the 16 children with and 31 children without CNS involvement during the acute episode of HUS (n=47)
Full-scale and subscale IQ CNS involvement during acute
episode of HUS (n=16) b
No CNS involvement during acute
episode of HUS (n=31)
p-value
Full-scale IQ 105 (62–127)b 104 (54–127) 0.62
Verbal comprehension index 99 (81–124) 103 (69–130) 0.49
Similarities 11 (6–14) 12 (4–17) 0.51
Vocabulary 10 (5–15) 10 (3–14) 0.76
Comprehension 9 (6–16) 10 (7–19) 0.31
Perceptional reasoning index 108 (81–117) 108 (61–129) 0.81
Block design 12 (5–16)b 12 (5–18) 0.74
Picture concepts 10 (6–14) 10 (2–13) 0.84
Matrix reasoning 11 (8–14) 11 (2–18) 0.90
Working memory index 102 (56–135) 102 (54–144) 0.98
Digit span 10 (3–16) 10 (3–16) 0.78
Arithmetic 10 (2–17) 11 (1–19) 0.60
Processing speed index 96 (71–129)b 103 (65–129) 0.29
Coding 9 (4–14)b 10 (4–14) 0.40
Symbol search 10 (5–16)b 12 (3–16) 0.40
Results are presented as the median IQ score, with the range in parenthesis
CNS, Central nervous system; HUS, hemolytic uremic syndrome
a Intellectual performance was assessed using the Wechsler Intelligence Scale 4th version
bOne patient (Table 1, patient no. 44) was not able to perform theWechsler Intelligence Scale 4th version except the subtests “Block design”, “Coding”
and “Symbol Search.. His results are only included in the subtests, processing speed index and full scale IQ
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When participants with additional neurodevelopmental co-
morbidities were excluded, the neurodevelopmental outcome
compared to normal controls was still impaired except for the
pure motor and the adaptive fine motor domain (p>0.07).
Participants with a history of ESRD (n=5) had significantly
poorer results in the domain static balance than those without
ESRD [−1.9 (range −3.0 to −0.7) vs. −0.2 (−3.0 to 1.7); p=
0.003].
Motor therapies (including psychomotor, physical and
ergotherapy) were reported for nine children (19 %). There
were no significant differences between children with and
without CNS involvement in terms of frequency of motor
therapies (6/31 vs. 3/16, respectively; p=0.64).
Neurodevelopmental outcome in children with STEC-HUS
Table 6 presents the developmental outcome for children with
only STEC-HUS—which was the commonest HUS form pres-
ent in the study cohort (n=38). Compared to normal controls,
children with STEC-HUS showed a favorable intellectual
outcome. In contrast, neuromotor outcome was impaired
in the ZNA domains “adaptive gross motor” and “associated
movements”. In these domains, 34 % and 39 % respectively
performed poorer than the 10th percentile (Table 6).
Prognostic factors
Potential risk factors for poorer IQ were evaluated in a multi-
variate linear regression analysis . Socioeconomic status (ß=
0.474, p=0.001) was the only factor associated with the full-
scale IQ whereas CNS involvement (ß=−0.074, p=0.62),
duration of hospital stay (ß=−0.257, p=0.08) and eGFR at
time of discharge (ß=−0.117, p=0.41) were not.
Discussion
The majority of follow-up studies of children with HUS have
focused on renal outcome after HUS episode [2–5, 9, 15].
Data on neurodevelopmental outcome, however, are scarce,
with only few published studies of various designs and case
series available [18, 30], and little information on long-term
Table 5 Motor performancea data of all patients (n=47) and of the 16 children with and 31 children without central nervous system (CNS) involvement
during the acute episode of hemolytic uremic syndrome (HUS)
Zurich Neuromotor
Assessment domains
All patients CNS involvement during
acute episode of HUS (n=16)
No CNS involvement during acute
episode of HUS (n=31)
p valued
z-score <P10b p valuec
Timed performances
Pure motor 0.10 (−5.5 to 4.6) 15 % (7/47) 0.73 0.25 (−5.5 to 1.7) 0.10 (−2.4 to 4.6) 0.65
Adaptive fine motor −0.30 (−3.6 to 3.5) 28 % (13/46) 0.042* −0.23 (−2.7 to 1.2) −0.30 (−3.6 to 3.5) 0.72
Adaptive gross motor −1.00 (−7.5 to 2.5) 36 % (16/45) 0.003* −1.30 (−7.5 to 2.2) −1.00 (−3.4 to 2.5) 0.19
Static balance −0.25 (−3.0 to 1.7) 17 % (8/46) 0.007* −0.20 (−3.0 to 0.6) −0.30 (−3.0 to 1.7) 0.84
Associated movements −1.10 (−3.2 to 2.0) 38 % (18/47) <0.001* −1.25 (−3.2 to 0.2) −0.90 (−2.3 to 2.0) 0.10
*Significant difference at p< 0.05
Results are presented as the median z-score with the range in parenthesis
aMotor performance was assessed using the Zurich Neuromotor Assessment (ZNA)
b<P10 indicates the proportion of patients presenting with z-scores of<−1.282 (i.e. results<10th percentile)
c p value calculated for z-score difference to norm
d p value calculated for z-score difference between patients with and without CNS involvement
Table 6 Neurodevelopmental outcome of 38 children with STEC-HUS
Assessment tool Neurodevelopmental outcome
Score p value <P10a
Wechsler Intelligence Scale
4th version
Full-scale IQ 104.5 (82–127) 0.003*
Verbal comprehension index 104 (79–124) 0.10
Perceptional reasoning index 108 (86–123) 0.001*
Working memory index 102 (82–135) 0.06
Processing speed index 100 (79–129) 0.25
Zurich Neuromotor Assessment
Timed performances
Pure motor 0.1 (−2.4 to 4.6) 0.91 11 % (4/38)
Adaptive fine motor −0.3 (−3.6 to 3.5) 0.18 24 % (9/38)
Adaptive gross motor −0.8 (−7.5 to 2.5) 0.012* 34 % (13/38)
Static balance −0.2 (−2.9 to 1.7) 0.13 11 % (4/38)
Associated movements –1.2 (−3.2 to 2.0) <0.001* 39 % (15/38)
*Significant difference at p< 0.05
Results are presented as the median score with the range given in
parenthesis. Comparison is to test norms (mean IQ 100, standard devia-
tion 15)
STEC-HUS, Escherichia coli hemolytic uremic syndrome
a<P10 indicates the proportion of patients presenting with z-scores of<
−1.282 (i.e. results<10th percentile)
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outcome. We report here our results from a single-center
cross-sectional investigation assessing neurocognitive and
neuromotor long-term outcome of pediatric patients after
STEC-HUS, P-HUS or aHUS. In our study we also examined
the role of CNS involvement during the acute episode of HUS
on subsequent neurodevelopment. In contrast to previous
studies focusing on STEC-HUS [17–19], we expressly includ-
ed patients with different HUS forms (STEC-HUS, P-HUS
and aHUS) even though apart from thrombotic microangiop-
athy the underlying pathomechanisms of these HUS forms do
differ.
Our patient series showed an overall favorable
neurodevelopmental outcome after a history of HUS, with a
normal full-scale IQ. Furthermore, the intellectual perfor-
mance of our patients was not affected by CNS impairment
during the acute HUS episode. Only socioeconomic status
was positively correlated with full-scale IQ, which is consis-
tent with findings in healthy controls [26]. Socioeconomic
status is also a strong predictor of intellectual outcome in other
populations at risk, such as preterm born children [31] or
children with congenital heart defects [32].
One-third of our study patients presented with neurological
symptoms during the acute episode of HUS, particularly in the
form of seizures and altered consciousness, including four of
the six patients with P-HUS, but none of those with aHUS.
These findings are consistent with those of previous studies on
neurological involvement in patients with STEC-HUS (19–
30 % showing neurological symptoms) [2, 9, 33] and P-HUS
patients (16–56 % with neurological symptoms) [14, 34, 35].
There are no evidence-based guidelines on the treatment of
CNS complications in HUS. Nathanson et al. [16] suggested
that plasmapheresis might have some benefit in children with
severe CNS complications. In our series, only two children
with STEC-HUS underwent plasmapheresis for severe neuro-
logical complications with full neurological recovery.
Our findings are consistent with the results of three previ-
ous studies. Schlieper et al. [17] demonstrated a favorable
neurocognitive outcome in children at a mean age of 8.6 years
(±3.1 SD) and mean duration of 4.1 years (±2.4 SD) after the
diagnosis of HUS, with normal full-scale and subscale IQ
values in 91 children after HUS (without specification of
HUS type), including nine children with seizures or coma
during the acute episode of HUS. However, these authors
did observed mild deficits in language domains in patients
with severe acute HUS [17]. Qamar et al. [18] described a
normal intellectual outcome in all seven patients studied de-
spite severe neurological complications during the acute dis-
ease. Bauer et al. [19] also reported a favorable neurocognitive
outcome in 25 children affected by the STEC-HUS outbreak
in 2011 in Germany due to E. coli O104:H4. However, these
authors observed a slightly lower full-scale IQ in children with
CNS involvement vs. those without CNS involvement during
HUS. Other studies focusing on neurological involvement in
adult patients with STEC-HUS due to E. coli O104:H4 also
suggested a good neurological outcome [36].
In our series, only six children (12 %), including four with
ESRD, had a full-scale IQ of <85, indicating an unfavorable
intellectual outcome. Moreover, two of these six children had
a history of severe cerebral complications after P-HUS.
Patients with a history of ESRD showed a significant
poorer neurocognitive outcome after HUS compared to pa-
tients without ESRD after HUS. The development of ESRD,
particularly in infancy, is a known risk factor for impaired
neurocognitive outcome [37].
In our study, neuromotor performance was less favorable
than intellectual outcome, with a poorer outcome particularly
in fine and gross motor functioning, static balance and move-
ment quality. Normal performance observed in the domain of
pure motor functioning. This is an interesting finding. In this
domain, simple motor tasks, such as repetitive or sequential
finger, hand or foot movements, are performed. It is conceiv-
able that impairments only become apparent when more com-
plex motor functions, such as adaptive motor performances,
are required. Motor performance did not differ between chil-
dren with and without CNS impairment during acute HUS
episode. Qamar et al. [18] also studied neuromotor outcome
after HUS, reporting impaired fine motor and clumsiness in
four of seven patients with severe neurological complications
during the acute HUS episode. In our study, a significant
proportion of patients (15–38 %) had motor performance
below the 10th percentile. This poorer motor performance is
clinically significant as children who perform below the 10th
percentile often have difficulties participating in activities of
daily life and demonstrate poorer hand writing skills and
slower speed. However, we did not assess the impact of motor
difficulties on daily life. Of note, motor therapies were report-
ed in 19 % of our patients independently of CNS involvement
during HUS.
The pathophysiological mechanisms leading to impaired
neuromotor outcome after HUS remain to be clarified. In
addition to cerebral thrombotic microangiopathy, factors such
as electrolyte imbalances (e.g. severe hyponatremia), hypo-
osmolality, azotemia, arterial hypertension and the direct toxic
effects of Shiga toxin in STEC-HUS may be involved in
pathogenetic mechanisms of neurological impairment [19,
38]. Impaired neuromotor outcome can also be found in other
cohorts of pediatric patients with various diseases, such as
congenital diaphragmatic hernia [39] or congenital heart dis-
ease [40]. Impaired neuromotor findings also suggest disease-
unrelated factors leading to an adverse neuromotor perfor-
mance, such as factors attributable to long hospital stay sec-
ondary to more severe course of a disease or more parental
protection and less experience.
This study has several limitations. Due to its retrospective
and cross-sectional study design, information on neurological
complications during the acute illness phase was obtained
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retrospectively by chart review and parental interviews. Apart
from the parents’ medical report, no formalized data on the
neurodevelopmental status prior to HUS were available.
Furthermore, the number of patients with P-HUS and aHUS
was too small to analyze outcome in relation to HUS type.
In conclusion, the results of this study show that children
and adolescents with HUS have a normal intellectual out-
come, but a significant impairment in motor outcome.
Neurological complications during the acute episode of HUS
were not associated with a poorer neurodevelopmental out-
come. Therefore, long-term observation of children after HUS
is advisable for the early detection of neurodevelopmental
deficits.
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